ENLIVEX THERAPEUTICS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.32 USD | -5.71% |
|
-16.46% | -51.11% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 24.55M |
|---|---|---|---|---|---|
| Net income 2024 * | -16M | Net income 2025 * | -12M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.53
x | P/E ratio 2025 * |
-2.4
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.57% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -5.71% | ||
| 1 week | -16.46% | ||
| Current month | -65.17% | ||
| 1 month | -67.57% | ||
| 3 months | -51.82% | ||
| 6 months | -8.33% | ||
| Current year | -51.11% |
1 week
1.15
1.56
1 month
1.154.59
Current year
1.154.59
1 year
1.154.59
3 years
1.1513.95
5 years
1.1544.90
10 years
1.1544.90
| Managers | Title | Age | Since |
|---|---|---|---|
Oren Hershkovitz
CEO | Chief Executive Officer | 47 | 19-11-15 |
Dror Mevorach
FOU | Founder | 68 | 08-12-31 |
| Director of Finance/CFO | 47 | 15-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Shai Novik
CHM | Chairman | 58 | 19-03-25 |
Avri Havron
BRD | Director/Board Member | 75 | 13-12-31 |
Brian Schwartz
BRD | Director/Board Member | 52 | 20-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 1.32 | -5.71% | 108,658 |
| 24-04-18 | 1.4 | -5.41% | 92,429 |
| 24-04-17 | 1.48 | +2.07% | 390,084 |
| 24-04-16 | 1.45 | +11.54% | 406,432 |
| 24-04-15 | 1.3 | -17.72% | 842,440 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Calendar
2024-05-23
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.32
USD
Average target price
7
USD
Spread / Average Target
+430.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -51.11% | 24.55M | |
| -3.10% | 102B | |
| +2.11% | 96.37B | |
| -1.80% | 21.37B | |
| -17.75% | 20.92B | |
| -6.91% | 18.64B | |
| -42.00% | 16.4B | |
| -28.19% | 13.53B | |
| +0.18% | 13.28B | |
| +19.90% | 10.85B |
- Stock Market
- Equities
- ENLV Stock
